Participants in studies of the psychedelic, which is up for U.S. approval, tell WSJ they felt pressure to report positive outcomes
The Food and Drug Administration is expected within days to decide whether to approve the drug, known as MDMA, for treatment of post-traumatic stress disorder. Approval would be a milestone in decades of efforts to decriminalize the use of psychedelics.
I love the Wall Street Journal economic journalism, but I’m not willing to pay like 35 bucks for a subscription lol. Maybe if I was an entrepreneur who needed it for business. But for an everyday user, there’s no need for it to be that expensive.